Algorithm Sciences is a development-stage biopharmaceutical company focused on optimizing treatment for rare cardiovascular diseases (CVDs). The company’s lead product candidate targets rare CVDs and Algorithm Sciences says its tools and technologies can deliver therapies to achieve improved outcomes. Algorithm Sciences is a Laidlaw Venture Partners portfolio company. The company stated it will invest proceeds from the Series B to further develop its pipeline, including the lead product candidate for rare CVDs. The announcement was made in a press release dated April 20, 2021; no operating metrics such as revenue or user counts were disclosed.

Total raised

$5M

Funding rounds

1

Latest round

Series B

Latest activity

Apr 2021